MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, RLYB had $22,677K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$22,677K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
16,016 -19,142
Depreciation and amortization
35 54
Net accretion of discounts/premiums on debt securities
-113 -363
Share-based compensation
1,047 3,493
Equity method investment, realized gain on disposal
22,350 -
Loss on investment in joint venture
0 -874
Prepaid expenses, operating lease right-of-use assets and other current assets
773 2,085
Accounts payable
150 -159
Accrued expenses and operating lease liabilities
-350 -832
Deferred revenue
-212 -424
Net cash used in operating activities
-6,550 -18,584
Purchases of marketable securities
738 9,884
Proceeds from maturities of marketable securities
9,965 25,500
Proceeds from sale of common stock received from sale of joint venture
20,000 -
Investment in joint venture
0 1,500
Net cash provided by investing activities
29,227 14,116
Proceeds from the issuance of common stock from a securities purchase agreement
0 0
Proceeds from the issuance of common stock under the stock purchase plan
0 10
Payments of offering costs
0 0
Net cash provided by financing activities
0 10
Net increase in cash and cash equivalents
22,677 -4,458
Cash and cash equivalents at beginning of period
13,903 -
Cash and cash equivalents at end of period
32,122 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Rallybio Corp (RLYB)

Rallybio Corp (RLYB)